Checkpoint inhibitor-related renal vasculitis and use of rituximab
The percentage of patients with cancer eligible for checkpoint inhibitor (CPI) therapy has increased rapidly over the past few years and approaches 45%. As a result, more cases of CPI-related nephrotoxicity, including a rare subset with vasculitis, are being reported. To elucidate the clinical prese...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2020-10-01
|
| シリーズ: | Journal for ImmunoTherapy of Cancer |
| オンライン･アクセス: | https://jitc.bmj.com/content/8/2/e000750.full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|